Company Overview and News

Hitachi's (HTHIY) Management on Q4 2017 Results - Earnings Call Transcript

2018-04-29 seekingalpha
Since it's time, let us begin the Hitachi Ltd. Results Announcement for Fiscal 2017. Our presenters here is that Mr. Mitsuaki Nishiyama, Senior Vice President and Executive Officer, CFO; in the same group Mr. Tomomi Kato, General Manager, Financial Strategy Division; Brand Communications General Manager, Mr. Yasuo Hirano. Now in regard to the overall about the results, Mr. Nishiyama will present.
9086 HTCIY HMTLF MIELF HMTLY 4217 MEL MIELY 6501 6503 5486 HTHIY 8586

EU fines Japanese firms over price-fixing cartel for capacitors

BRUSSELS – The European Commission said Wednesday it imposed €254 million in fines on eight firms, mostly Japanese companies, for operating an illegal price cartel for capacitors.
4217 PCRFY 6997

EU fines 8 Japanese companies over electric component cartel

BRUSSELS (AP) — The European Union has fined eight Japanese companies a combined $312 million for collusion in the electronic component market over a 14-year period.
4217 6997

EU fines capacitor producers 254 million euros for taking part in cartel

2018-03-21 channelnewsasia
BRUSSELS: EU antitrust regulators handed down a 254-million-euro (US$311.94 million) fine to eight capacitor producers on Wednesday for taking part in a cartel for more than a decade.
4217 6997

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...